Date: February 6, 2023
To: Enrolled Pharmacies
Re: Update: Emergency Tamiflu and Oseltamivir Shortage Compounding Instructions
___________________________________________________________________________________________________________________________________________________
This notice informs providers that due to the widespread availability of generic Tamiflu (oseltamivir), the Department of Healthcare and Family Services (HFS) will end the temporary procedures outlined in the December 9, 2022 provider notice effective March 1, 2023. This affects the Medicaid fee-for-service (FFS) program and the managed care organizations (MCOs).
Effective March 1, 2023, the Department will no longer reimburse providers for dispensing brand name Tamiflu or for compounding suspensions with brand name Tamiflu. While there is no current shortage of the oral suspension, compounding with the generic oseltamivir will be allowed only in emergency situations, as there still may be localized areas of shortage where demand is high.
The drugs will be removed as preferred products on the Preferred Drug List, and prior authorization will again be required for brand Tamiflu under the FFS program and the MCOs.
Questions regarding this notice may be directed to a pharmacy consultant in the Bureau of Professional and Ancillary Services at 877-782-5565 for FFS claims, or the appropriate MCO.
Kelly Cunningham, Administrator
Division of Medical Programs
